Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Alpha1 Inhibitor Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 3445-D

    Medicare Part B Step Therapy Alpha1-Proteinase Inhibitors

    Customize your policy alerts

    Sign up for zing_health Policy 3445-D alerts

    Get alerted when Policy 3445-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs preferred-product sequencing and prior authorization exceptions for alpha1-proteinase inhibitor products under Medicare Part B. It affects members who are new to treatment with a non-preferred product and requires a clinical exception for non-preferred coverage.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Alpha1-Proteinase Inhibitors
    Policy CodePolicy 3445-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization request for a non-preferred alpha1-proteinase inhibitor when seeking coverage under the clinical exception process.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Preferred products
    2Non-preferred products
    365 daysPrior-treatment lookback
    2Exception pathways

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Non-Preferred Product Coverage

    Non-preferred Product Coverage

    Coverage for a non-preferred product is provided when either of the following criteria is met:

    At least one criterion

    • Recent non-preferred treatment: The member has received treatment with the non-preferred product in the past 365 days.Past 365 days
    • Intolerance to preferred products: The member has had a documented intolerable adverse event to both preferred products, Prolastin-C and Zemaira, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.Both preferred products

      An expected active-ingredient adverse event described in the prescribing information does not satisfy this criterion.

    An adverse event attributed to the active ingredient that is expected according to the prescribing information does not satisfy the intolerance-based exception for non-preferred product coverage.

    Exception Requests and Documentation

    Prior Authorization

    Prior Authorization Required for Non-Preferred Products

    Submit a prior authorization request under the clinical exception pathway when seeking coverage for a non-preferred alpha1-proteinase inhibitor.

    • The request must describe the clinical circumstances that exclude use of the preferred product.
    • Step therapy applies in addition to any applicable NCD, LCD, and Medicare Part B utilization management requirements.
    Note

    Meet a Non-Preferred Product Exception

    For a member new to treatment with a non-preferred product, coverage may be approved when either exception pathway is met.

    • The member received treatment with the non-preferred product within the past 365 days.
    • The member has a documented intolerable adverse event to both preferred products: Prolastin-C and Zemaira.

    Unsupported block type: documentation休息?

    Denial Risk

    Exception Criteria Not Met

    The non-preferred product exception is not met when neither qualifying pathway is documented, and coverage may be denied.

    • No treatment with the non-preferred product is documented within the past 365 days.
    • There is no documented intolerable adverse event to both Prolastin-C and Zemaira.
    • The reported adverse event is expected and attributed to the active ingredient as described in the prescribing information.

    Policy Background

    This policy applies to alpha1-proteinase inhibitor products administered under Medicare Part B. Prolastin-C and Zemaira are the preferred products; Aralast NP and Glassia are non-preferred products. Coverage of a non-preferred product requires a clinical exception, supported by either treatment with the requested product within the past 365 days or documented intolerable adverse events to both preferred products that were not expected active-ingredient adverse events described in the prescribing information. Applicable Medicare National Coverage Determinations, Local Coverage Determinations, and other Part B utilization management programs may also apply.

    Initial Non-Preferred Product Exception

    Initial Non-preferred Product Exception

    For members who are new to treatment with a non-preferred product, coverage is provided when either of the following exception criteria is met:

    At least one exception criterion

    • Prior non-preferred treatment: The member has received treatment with the requested non-preferred product in the past 365 days.Past 365 days
    • Intolerable adverse events to preferred products: The member has a documented intolerable adverse event to both Prolastin-C and Zemaira, and the event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.Both preferred products

      An expected active-ingredient adverse event described in the prescribing information does not satisfy this exception criterion.

    Preferred Product Sequencing

    StepPreferred productsNon-preferred product coverage
    1Prolastin-C or ZemairaAralast NP or Glassia is covered when the member received the requested product within the past 365 days, or had a documented intolerable adverse event to both preferred products that was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Alpha1-Proteinase Inhibitors
    Policy CodePolicy 3445-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization request for a non-preferred alpha1-proteinase inhibitor when seeking coverage under the clinical exception process.
    SourceLink
    On This Page
    Non-Preferred Product CoverageException Requests and DocumentationPolicy BackgroundInitial Non-Preferred Product ExceptionPreferred Product Sequencing